Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination?

The hepatocyte growth factor and c-Met receptor tyrosine kinase axis plays a key role in normal biological functions including embryogenesis, cell proliferation, and tissue regeneration (1). Several malignancies, including lung cancer, exploit abnormal activation of c-Met for carcinogenesis. Early efforts to target c-Met in lung cancer were unsuccessful but that has changed recently with the development of MET tyrosine kinase inhibitors (TKI) targeting MET exon 14 skipping (METex14) mutation (2-4). The MET TKIs capmatinib and tepotinib are FDA-approved in the United States for patients with METex14 mutation-positive non-small cell lung cancer (NSCLC), and approved by the EMA in Europe as a second-line treatment option. Savolitinib is approved in the second-line setting in China. Apart from MET TKIs, amivantamab [a bispecific antibody targeting epidermal growth factor receptor (EGFR) and MET] and Sym015 (a mixture of two humanized monoclonal antibodies that degrade MET receptor by binding to its extracellular domain), have shown activity against METex14 positive NSCLC (5,6) (Figure 1). These MET TKIs and antibodies have shown activity against both de-novo and acquired MET-amplification in NSCLC but further studies are needed to delineate the role of these agents in treating patients with MET-amplified NSCLC (reviewed in Remon et al., 2023) (7).

Figure 1 Selected target therapies of the c-Met receptor. HGF, hepatocyte growth factor; PSI, plexin-semaphorin-integrin; IPT, immunoglobulin-like, plexin, transcription factors; TK, tyrosine kinase; MET, MMNG HOS transforming gene; TKI, tyrosine kinase inhibitor.

Treatment with MET TKIs currently benefits only a small proportion (4%) of patients with NSCLC that harbor METex14 mutation. However, c-Met overexpression is far more common than METex14 and MET amplification in patients with NSCLC at 30–70% (1). Previous efforts to target the hepatocyte growth factor (HGF) and c-Met axis using monoclonal antibodies proved to be unsuccessful (8-10). Similarly small molecule kinase inhibitors have not been effective against MET overexpressing tumors. The presence of c-Met overexpression does not indicate activation of the MET pathway and that may explain the lack of benefit. Advances in antibody design now allow targeted delivery of cytotoxic agents to the tumor cells and these antibody-drug conjugates (ADC) present a novel mechanism to target cancer cells. They target specific surface proteins expressed on cancer cells regardless of their role in cell signaling and survival.

Telisotuzumab vedotin (Teliso-V) is an ADC with a c-Met targeting humanized monoclonal antibody combined with the microtubule inhibitor monomethyl auristatin by a cleavable valine-citrulline peptide linker. The combination has approximately three molecules of monomethyl auristatin per antibody. In preclinical studies, Teliso-V is active against cancer cells overexpressing c-Met or with MET amplification and its activity is independent of the cell’s MET pathway activity (11). The cytotoxic activity of Teliso-V appears to be dependent on the cell surface expression of c-Met, and tumor cells with higher levels of c-Met expression are more sensitive to Teliso-V. A subsequent first in human trial reported favorable safety and promising activity for single agent Teliso-V in c-Met expressing NSCLC (12). However, studies in squamous NSCLC have shown limited response and severe toxicity with grade 5 pneumonitis (13,14).

In this phase Ib study by Camidge and colleagues evaluated the safety and efficacy of the combination of Teliso-V with the EGFR TKI erlotinib in patients with c-Met expressing advanced NSCLC in whom no other approved therapies were available (15). Archival tissue was required to confirm c-Met overexpression, MET exon 14 mutation, or MET amplification. c-Met-overexpression in this study was defined as histology (H)-score of 150 or greater. The study primarily focused on patients (n=31) with activating EGFR TK mutations (EGFRm) who had progressed on EGFR TKIs. Patients with activating EGFRm can develop resistance to EGFR TKIs due to on-target EGFR mutations, off-target bypass pathway signaling including MET amplification in 15–30% or lineage transformation (16,17). Combining Teliso-V with erlotinib can target MET pathway-activated tumors as well as tumors that express MET but do not depend on its signaling. The study enrolled 42 patients and 36 were evaluable for efficacy since six patients were not included in the efficacy analysis due to low H-score or no available tissue for H-score evaluation. Five EGFR wild-type patients were enrolled prior to study amendments that mandated the presence of EGFR mutation. The reported median progression-free survival (PFS) was 5.9 months, and the overall response rate (ORR) was 30.6%. In patients with EGFRm, the median PFS was 5.9 months and ORR of 32.1%, including one patient with complete response (CR). Sub-analysis identified that patients with EGFR T790M mutation (n=13) had a median PFS of 3.7 months versus 6.8 months in patients without EGFR T790M (n=15) mutation. Patients with high c-Met scores (H-score >225) had an ORR of 52.6% including one CR whereas there were no CRs and partial response (PR) of 12.5% in patients with low c-Met scores. Neuropathy was the most common adverse event, reported in 43% of patients and other unique adverse events included dermatitis acneiform (38%), keratitis (14%), and pulmonary embolism (14%). Adverse events were similar to prior studies of Teliso-V (18).

In this study, Teliso-V is a reasonably well-tolerated agent, which could be useful in EGFRm patients in whom there is an unmet need for effective treatments after progression on first-line therapy. In a prior study, single-agent Teliso-V in c-Met high EGFRm population had an ORR of 11.6%, whereas in this study the combination of erlotinib with Teliso-V in the c-Met high EGFRm population demonstrated an ORR of 32.1%; suggesting that the addition of erlotinib improved treatment efficacy (14). Presence of EGFR T790M mutations, which are resistant to 1st and 2nd generation EGFR TKIs, had a negative impact on the therapeutic efficacy of Teliso-V combined with erlotinib (15). A phase I/Ib study combining Teliso-V with the 3rd generation EGFR TKI osimertinib in patients with c-Met-overexpression who previously failed osimertinib, reported an ORR of 58%, while in this study the ORR of patients with c-Met-overexpression previously on osimertinib was 27% (15,19). The value of Teliso-V plus erlotinib may be mainly in regions of the world where osimertinib is unavailable—otherwise, the combination of Teliso-V plus osimertinib may be the more relevant combination.

The trial thoroughly examined the molecular biology of the tumors, providing data regarding EGFR wild-type versus EGFR mutant (del 19 versus L858R) versus EGFR rare or unknown mutations, EGFR T790M mutations, c-Met positive, c-Met high, and MET amplification status (15). While some of these data were based on archival tissue and may have changed over the course of treatment, perhaps resulting in misrepresentation of the actual biology of the tumor at the time of clinical trial enrollment, its level of detail highlights the critical need to understand the underlying biology in order to provide precision treatment. Additionally, ctDNA and ctRNA testing could provide valuable information when repeat solid tissue biopsy is not feasible.

Targeting of c-Met exemplifies the complex biology of cancer, and agents with a variety of targeting mechanisms—from TKIs to bispecific antibodies—are part of the collection of treatment options. ADCs are a welcome addition in the effort to target c-Met overexpression. Teliso-V for c-Met-overexpressing non-squamous NSCLC preliminarily demonstrates promising activity. This is particularly relevant for patients with EGFR activating mutations who have developed resistance to EGFR TKIs via c-Met overexpression. Teliso-V plus osimertinib is likely to represent a more effective combination than with first-generation EGFR TKIs, although this may still be relevant in regions where third-generation EGFR TKIs are unavailable. Biomarker identification is critical to the success of these therapies. The role of this new treatment combination in clinical practice needs additional study.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Translational Lung Cancer Research. The article has undergone external peer review.

Peer Review File: Available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-288/prf

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-288/coif). JS received consulting fees from Astra Zeneca, Jazz, Janssen, G1 therapeutics, Cardinal, Daiichi, Beigene, Takeda, Oncohost, Blueprint, GLG, Guidepoint, and payments or honoraria from Astra Zeneca, Jazz, Janssen, G1 therapeutics. The other author has no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Fu J, Su X, Li Z, et al. HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence. Oncogene 2021;40:4625-51. [Crossref] [PubMed]
2. Liang H, Wang M. MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis. Onco Targets Ther 2020;13:2491-510. [Crossref] [PubMed]
3. Wolf J, Seto T, Han JY, et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med 2020;383:944-57. [Crossref] [PubMed]
4. Paik PK, Felip E, Veillon R, et al. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med 2020;383:931-43. [Crossref] [PubMed]
5. Krebs M, Spira AI, Cho BC, et al. Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study. J Clin Oncol 2022;40:9008.
6. Camidge DR, Janku F, Martinez-Bueno A, et al. Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (METAmp/Ex14∆). J Clin Oncol 2020;38:9510.
7. Remon J, Hendriks LEL, Mountzios G, et al. MET alterations in NSCLC-Current Perspectives and Future Challenges. J Thorac Oncol 2023;18:419-35. [Crossref] [PubMed]
8. Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2013;31:4105-14. [Crossref] [PubMed]
9. Mok TS, Geater SL, Su WC, et al. A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma. J Thorac Oncol 2016;11:1736-44. [Crossref] [PubMed]
10. Banck MS, Chugh R, Natale RB, et al. Abstract A55: Phase 1 results of emibetuzumab (LY2875358), a bivalent MET antibody, in patients with advanced castration-resistant prostate cancer, and MET positive renal cell carcinoma, non-small cell lung cancer, and hepatocellular carcinoma. Mol Cancer Ther 2015;14:A55.
11. Wang J, Anderson MG, Oleksijew A, et al. ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence. Clin Cancer Res 2017;23:992-1000. [Crossref] [PubMed]
12. Strickler JH, Weekes CD, Nemunaitis J, et al. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. J Clin Oncol 2018;36:3298-306. [Crossref] [PubMed]
13. Waqar SN, Redman MW, Arnold SM, et al. A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). Clin Lung Cancer 2021;22:170-7. [Crossref] [PubMed]
14. Camidge DR, Bar J, Horinouchi H, et al. Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2022;40:9016.
15. Camidge DR, Barlesi F, Goldman JW, et al. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol 2023;41:1105-15. [Crossref] [PubMed]
16. Ramalingam SS, Yang JC, Lee CK, et al. Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2018;36:841-9. [Crossref] [PubMed]
17. Schoenfeld AJ, Chan JM, Kubota D, et al. Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer. Clin Cancer Res 2020;26:2654-63. [Crossref] [PubMed]
18. Camidge DR, Otterson GA, Clark JW, et al. Crizotinib in Patients With MET-Amplified NSCLC. J Thorac Oncol 2021;16:1017-29. [Crossref] [PubMed]
19. Goldman JW, Horinouchi H, Cho BC, et al. Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC). J Clin Oncol 2022;40:9013.